Pyridoxine
Contents
Description
Pyridoxine (Vitamin B6) is used in the treatment of hereditary sideroblastic anemia, particularly X-linked sideroblastic anemia caused by ALAS2 mutations. It acts as a cofactor for delta-aminolevulinic acid synthase, the first enzyme in heme biosynthesis. Some patients with hereditary sideroblastic anemia respond to high-dose pyridoxine supplementation with improved hemoglobin levels.
Indications & Therapeutic Use
Hereditary sideroblastic anemia, pyridoxine-responsive anemia, vitamin B6 deficiency
Linked Diseases:
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Pyridoxine — GNH India
60 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | Pyridoxine |
| Active Ingredient | Pyridoxine hydrochloride |
| Drug Class | Hereditary sideroblastic anemia |
| Manufacturer | Various |
| Dosage Forms | Oral tablets 25mg, 50mg, 100mg; Injectable solution 100mg/mL |
| Medical Code | A11HA02 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Countries | 8 countries |